Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality
SHANGHAI and HONG KONG, April 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it has released results from four preclinical studies in poster...
Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU,China, April 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for limertinib as...
Concord Medical Files Annual Report on Form 20-F for Fiscal 2024
BEIJING, April 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "Annual Report") with the U.S. Securities and Exchange...
Zepp Health Corporation Files 2024 Annual Report on Form 20-F
MILPITAS, Calif., April 26, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has filed its annual report on Form 20-F for the full year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report...
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
HONG KONG, April 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical Products Administration (NMPA) for its supplementary New Drug Application (sNDA) for use as a monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small...
Baijiayun Announces Plan to Invest Tens of Millions of Dollars Over Five Years to Build New Ecosystem for Autism Rehabilitation
BEIJING, April 25, 2025 /PRNewswire/ -- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ: RTC), a one-stop AI video solution provider, announced a Letter to Investors, in which Baijiayun CEO Mr. Yi Ma stated that following its partnership with Xinlantian, the company plans to invest tens of millions of dollars over the next five years to establish new ecosystem...
Ping An Reports Steady 2.4% Growth In Operating Profit Attributable to Shareholders of the Parent Company in Q1 2025, Life & Health NBV Jumps 34.9% YoY, Group Total Assets...
HONG KONG and SHANGHAI, April 25, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) today announced its first quarter financial results for the three months ended March 31, 2025. With macroeconomic policies continuing to exert their effects, China's economy achieved a steady start, maintaining an...
WATERDROP FILES ANNUAL REPORT ON FORM 20-F FOR FISCAL YEAR 2024
BEIJING, April 25, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on April...
Gleneagles Hospital Penang Introduces Southeast Asia’s First SOMATOM Pro.Pulse Dual Source CT Scanner
KUALA LUMPUR, April 25, 2025 /PRNewswire/ -- Gleneagles Hospital Penang today launched the new SOMATOM Pro.Pulse Computed Tomography (CT) Scanner, the very first of its kind in Southeast Asia. This cutting-edge technology enables faster, more accurate diagnostics - supporting better treatment decisions, improved outcomes and a more comfortable patient experience across the region. ...
Meihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year Results
YANGZHOU, China, April 25, 2025 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced its financial results for the fiscal year ended December 31, 2024. All amounts below are in U.S. dollars....
